Exagen Inc.

NASDAQ:XGN

Medical - Diagnostics & Research

Healthcare
$3.90 +3.84%

+$0.16 today

Market cap
$99.50M
Beta
2.02
P/E (TTM)
-5.2
EPS (TTM)
-$0.85
52W Low $2.59High $12.23

Volume 0.47M

Average 0.39M

XGN Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Exagen Inc.NASDAQ: XGN

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $36K, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $87K.

Context

  • Income tax expense amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $36K or moves back toward the trailing-twelve-month quarterly average of $21.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$36K+176.9% QoQ
Last fiscal yearDec 2025
$51K+325.0% YoY
LTMMar 2026
$87K+625.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+325.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
51K USD
Year-over-year change
+325.0%
4-year CAGR
-26.5%

Income Tax Expense vs competitors

How XGN compares with its peers on the latest reported figures

  • XGN's LTM Mar 2026 income tax expense of $87K is the 3rd highest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of +625.0% is the 2nd highest of 6, against a peer median of -89.0%.
  • Income tax expense amounts to 0.1% of revenue for XGN, versus a peer median of 0.1%.
XGN Competitors Peer median
Income Tax Expense for XGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$89.84M +889.7%+153.5%41.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$413K ——0.3%
XGNExagen Inc.LTM Mar 2026$87K +625.0%—0.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026$83K +359.4%—0.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
SMTISanara MedTech Inc.LTM Mar 2026$0 ——0.0%
BIOABioAge Labs, Inc.LTM Mar 2026$0 ——0.0%
STXSStereotaxis, Inc.LTM Mar 2026$0 ——0.0%
SGHTSight Sciences, Inc.LTM Mar 2026-$20K -107.7%-40.3%0.0%
MDXHMDxHealth S.A.FY2025-$1.86M -586.1%—1.7%
NEONeoGenomics, Inc.LTM Jun 2026-$2.67M -89.0%—0.3%
Peer median (excluding XGN) $0-89.0%+56.6%0.1%

Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.3M45.56M52.55M55.64M66.58M
Cost of Revenue20.59M24.21M23.09M22.53M27.78M
Gross Profit27.71M21.35M29.46M33.11M38.8M
Gross Margin57.4%46.9%56.1%59.5%58.3%
Research & Development7.24M9.88M4.87M5.38M6.25M
Selling, General & Admin44.54M52.02M47.43M41.37M46.62M
Operating Expenses51.78M67.4M52.29M46.75M52.87M
Depreciation & Amortization948K1.56M2.17M1.72M2.12M
EBITDA(23.1M)(43.66M)(19.15M)(11.15M)(13.46M)
EBITDA Margin-47.8%-95.8%-36.4%-20.0%-20.2%
Operating Income(24.07M)(46.05M)(22.84M)(13.64M)(14.07M)
Operating Margin-49.8%-101.1%-43.5%-24.5%-21.1%
Interest Income16K830K1.52M767K289K
Interest Expense2.63M2.45M2.34M2.23M4.32M
Other Income / Expenses(2.61M)(1.62M)(819K)(1.47M)(5.83M)
Income Before Tax(26.68M)(47.67M)(23.66M)(15.1M)(19.9M)
Pre-Tax Margin-55.2%-104.6%-45.0%-27.1%-29.9%
Income Tax Expense175K(282K)33K12K51K
Net Income(26.85M)(47.39M)(23.69M)(15.12M)(19.95M)
Net Margin-55.6%-104.0%-45.1%-27.2%-30.0%
EPS (Basic)(1.68)(2.77)(1.34)(0.83)(0.93)
EPS (Diluted)(1.68)(2.77)(1.34)(0.83)(0.93)
Weighted Avg Shares15.97M17.08M17.68M18.2M21.56M
Weighted Avg Shares (Diluted)15.97M17.08M17.68M18.2M21.56M

Exagen Inc.

NASDAQ:XGN

Intrinsic Alpha fair value

Locked

Current Price

$3.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.